Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 4, 2019

View Archived Issues

CTLA-4 plus PD-1 equals more than the sum of its parts

Serum endocan as biomarker to predict postablation recurrence of HCC

Novel CAR.CD30 T-cell therapy shows potential in vivo activity

Progranulin as new risk biomarker for the development of sepsis

Novel miRNA biomarker panel for predicting mortality in pediatric patients with ARDS

NTS2-selective compounds with promising activity in preclinical models of pain

FDA approves IND for first-in-human study of affinity-tuned CAR-T cell product AIC-100

Daiichi Sankyo and Sarah Cannon initiate first-in-human study of DS-7300

FDA clears IND application for phase I study of FX-201

NexImmune receives IND clearance for phase I/II study of NEXI-001

ORYX announces positive early clinical data for oncolytic virus ParvOryx

Rinvoq meets primary and all ranked secondary endpoints in phase III SELECT-PsA 2 study

BGS-2019: a new GMPS inhibitor for the treatment of lupus nephritis

BCX-9250 enters phase I development for treatment of fibrodysplasia ossificans progressiva

OB-002 significantly reduces both primary and metastatic breast cancer in vivo

Promentis Pharmaceuticals announces update on phase II development of SXC-2023

Neuropore Therapies divulges PIK3C3 inhibitors

Oligomannate approved in China for mild to moderate AD

University of Illinois discloses FOXM1 inhibitors

Enanta Pharmaceuticals identifies compounds for RSV infections

Erytech announces new milestones in TRYbeCA1 phase III study of eryaspase

HIV replication inhibitors detailed in ViiV Healthcare patent

VCP inhibitors patented by University of Pittsburgh

RP-7214: a novel DHODH inhibitor with oral activity in preclinical AML models

Neuronal insulin resistance linked to age-related dementia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...